Femtosecond Intrastromal Lenticule Implantation (Fili) For Management Of Moderate To High Hyperopia- 68 Months Outcomes And Clinical Experience
Published 2022 - 40th Congress of the ESCRS
Reference: FPT07.06 | Type: Free paper | DOI: 10.82333/6992-hf09
Authors: Hemali Dipakkumar Bhavsar* 1 , Sri Ganesh 1 , Sheetal Brar 1
1Department of phaco- refractive surgery,Nethradhama superspeciality eye hospital,Bangalore,India,Bangalore,India
Purpose
Setting
Methods
Eligible patients who underwent FILI for moderate to high hyperopia from July 2013 to October 2020 were included. A donor SMILE lenticule, matched for refractive error was implanted into the recipient’s corneal pocket created using a femtolaser at 160 microns depth. Visual and refractive outcomes and long term complications were evaluated at the end of a mean follow-up of 68±17.28 months (5.6 years).
Results
42 eyes of 25 patients (mean age 27.29±5.52 years) were analysed. The mean SE reduced significantly from +5.5±1.96 to +0.66±1.17D at 68 months post-op. 71% (n=30) eyes were within ±1.00D of SE. Cumulative UDVA of 20/40 or better was achieved in 81% (n=34) of eyes. Efficacy and safety indices were 0.86±0.19 and 1.17±0.39, respectively. There was significant increase in Kmean anterior, central corneal thickness, Q-value, corneal HOAs and decrease in Kmean posterior 2 weeks post-op, without any significant change in these parameters thereafter, p >0.05. 4 eyes of 3 patients underwent enhancement and another 4 eyes underwent explantation of lenticule followed by exchange (2 eyes) and hyperopic LASIK (2 eyes). No eye lost >1 line of CDVA.
Conclusions
At 68 months, FILI for moderate to high hyperopia, showed good safety, efficacy and reversibility. Modification of nomograms and surgical planning may be employed for further refinement of the outcomes.
Financial disclosure: Dr. Sri Ganesh and Dr. Sheetal Brar are consultatnts to Carl Zeiss Meditec.